Sunanda Desai
Vice President, Chemicals and Materials
The European chemical industry continues to face pressure from weak demand, high energy costs, and global overcapacity. Recovery remains fragile, prompting companies to reassess their portfolios and long-term competitiveness. Against this backdrop, M&A remains an important strategic tool for divesting structurally challenged assets, accessing higher-growth platforms, and reallocating capital toward innovation and higher-growth opportunities.
On September 25, BASF confirmed exploratory talks with RAG-Stiftung and Evonik Industries AG (Evonik) regarding a potential takeover. Reuters subsequently reported that BASF had made a €10.3 billion bid, which Evonik rejected.
A potential BASF–Evonik merger would unite two leading German chemical companies. Their portfolios overlap primarily in specialty chemicals and performance materials, with additional overlap in selected basic chemicals and intermediates. Despite these overlaps, their sources of differentiation remain distinct. BASF brings substantial scale, upstream integration, global manufacturing reach, and a broad portfolio. Evonik operates at scale in selected markets but is more focused on specialty and technology-driven platforms built on proprietary processes, application expertise, biotechnology, and high-value functional performance.
BASF’s core advantage is its breadth and ability to offer a one-stop-shop model. Its portfolio spans care chemicals, nutrition, performance materials, coatings, dispersions, additives, and industrial solutions, enabling it to supply multiple ingredient classes and support formulations from base chemistry through performance enhancement. Its Verbund model also delivers feedstock integration, manufacturing efficiency, and shared infrastructure. By contrast, Evonik is more technologically specialized, with leading positions built on difficult-to-replicate expertise in fermentation, surface modification, advanced drug delivery, specialty polymer architecture, and membrane design.
Overlapping Specialty Chemicals Portfolios, Differentiated Capabilities
BASF and Evonik compete in a number of overlapping specialty chemical businesses, including personal and home care, coating additives, polyurethane additives, and lubricant additives. The degree of overlap varies by specific product, application, customer segment, and geography; in several areas, the portfolios are complementary as well as competitive.
For example, BASF’s UV filters, surfactants, emulsifiers, enzymes, and formulation capabilities overlap with parts of Evonik’s Beauty & Personal Care portfolio, including functional ingredients, formulation technologies, biosurfactants, biotechnology-derived ingredients, and advanced delivery systems. Evonik also offers more specialized microbiome capabilities, including testing models and prebiotic, probiotic, and postbiotic concepts. Overall, the portfolios combine functional overlap in formulation and ingredient technologies with complementary areas of specialized expertise.
Evonik’s Distinct Technology Platforms
In healthcare, BASF offers a broad portfolio of pharmaceutical excipients and selected high-volume APIs, while Evonik focuses on advanced drug-delivery technologies, pharmaceutical lipids, and CDMO services. The portfolios are largely complementary, with limited direct overlap in areas such as enteric functional film coatings. Evonik would add expertise in lipid nanoparticles, polymers for long-acting injectables, and CDMO services. However, because BASF previously moved away from a service-based model, the strategic fit of Evonik’s CDMO operations within a combined portfolio would require careful evaluation.
In industrial biotechnology, Evonik would contribute integrated fermentation and commercial-scale manufacturing capabilities. Evonik’s IP-protected, fermentation-based rhamnolipid technology platform uses renewable sugar feedstocks to produce biosurfactants that have established applications in personal care and home care.
Evonik would also add specialized capabilities in engineered silica, metal oxides, particle and surface modification, and specialty polymers. These technologies serve formulation-intensive industrial and consumer applications and could broaden BASF’s materials offering, although the degree of complementarity would vary by product and market.
A potential merger with Evonik could broaden and strengthen BASF’s specialty chemicals portfolio in several technology-intensive areas while complementing its existing capabilities. The value of a combination would depend on effective integration, limited product and customer overlap, and the retention of specialized expertise. Realizing these benefits would require careful portfolio rationalization, an assessment of competitive overlap, and coordinated integration across technology, manufacturing, and customer-facing activities.
